Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T23761
(Former ID: TTDS00517)
|
|||||
| Target Name |
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
|
|||||
| Synonyms |
SERCA pump; SERCA; Calcium-transporting ATPase; Calcium pump; Ca2+-ATPase; Ca(2+)-ATPase; ATP4
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Malaria [ICD-11: 1F40-1F45] | |||||
| BioChemical Class |
Acid anhydrides hydrolase
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 7 Approved Drugs | + | ||||
| 1 | Artemisinin | Drug Info | Approved | Malaria | [1] | |
| 2 | Artemisinin SP | Drug Info | Approved | Malaria | [1] | |
| 3 | Artesunate | Drug Info | Approved | Malaria | [1] | |
| 4 | Dihydroartemisinin | Drug Info | Approved | Malaria | [1] | |
| 5 | OZ277 | Drug Info | Approved | Malaria | [1] | |
| 6 | Piperaquine | Drug Info | Approved | Malaria | [1] | |
| 7 | Pyronaridine | Drug Info | Approved | Malaria | [2] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Vanadate | Drug Info | Phase 3 | Psoriatic arthritis | [3] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 10 Inhibitor drugs | + | ||||
| 1 | Artemisinin | Drug Info | [1] | |||
| 2 | Artemisinin SP | Drug Info | [1] | |||
| 3 | Artesunate | Drug Info | [1] | |||
| 4 | Dihydroartemisinin | Drug Info | [1] | |||
| 5 | OZ277 | Drug Info | [1] | |||
| 6 | Piperaquine | Drug Info | [1] | |||
| 7 | Pyronaridine | Drug Info | [1] | |||
| 8 | Vanadate | Drug Info | [4] | |||
| 9 | THAPSIGARGIN | Drug Info | [5] | |||
| 10 | Cyclopiazonic acid | Drug Info | [4] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 4 | Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem. 2001 Apr 6;276(14):10782-7. | |||||
| REF 5 | Elucidation of the topography of the thapsigargin binding site in the sarco-endoplasmic calcium ATPase. Bioorg Med Chem. 2010 Aug 1;18(15):5634-46. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.